Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest IBD Stories

2009-10-26 22:53:59

Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC). Dr. Millie Long, of the University of North Carolina, Chapel Hill, and her colleagues examined the records of 26,403 patients with Crohn's disease...

2009-10-21 12:23:10

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology. CMV infects between 50% and 80% of adults in the United States. Most people who are infected have no symptoms, and the virus remains hidden but inactive in the body for the rest of the person's...

2009-08-21 08:22:50

For the first time, scientists have used a genetically engineered "friendly" bacterium to deliver a therapy.The treatment is for bowel disorders such as inflammatory bowel disease, which affects one in 400 people in the UK and for which there is no cure. The bacterium Bacteroides ovatus activates a protein when exposed to a specific type of sugar, xylan. In research to be published in Gut, the therapy has been proven to work in animals with colitis, one of the major forms of inflammatory...

2009-07-16 10:33:07

Based on serum bank material, BA profiling was applied in IBD patients and healthy controls which showed that most but not all BA species were decreased to a different extent in CD and UC. BA decreases were highly pronounced in CD patients with surgical interventions in the gut. On the other hand, UC patients with additional liver and gallbladder diseases showed clearly increased levels of those BAs that are synthesized directly in the liver (primary BAs), or subsequently modified by...

aeec07a612bbbcae426ac0c6147e6ae31
2009-06-16 12:05:00

Treating children with inflammatory bowel disease (IBD) usually involves the same steroids-based medication prescribed to adults. But such treatments can have negative side effects for kids and teens dealing with IBD.Dr. Raanan Shamir of Tel Aviv University's Sackler School of Medicine and Schneider Children's Medical Centre shows that there is another path to treating IBD in children: a nutritional formula that was first developed for astronauts. This supplement puts 60-70% of children with...

2009-06-02 11:23:28

Researchers at Penn State College of Medicine, working with biochemists, geneticists and clinicians at the University of Bern, Switzerland and in the United Kingdom, have discovered an enzyme that has a key role in inflammatory bowel disease (IBD). The team, co-led by Judith Bond, Ph.D., Distinguished Professor and Chair of Biochemistry and Molecular Biology at Penn State College of Medicine, and Daniel Lottaz, Department of Rheumatology and Clinical Immunology at the University of Bern,...

2009-06-02 06:00:00

New Insights into the Prediction of IBD Using Serology Testing Also Presented SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding a correlation between an important serologic marker used in the detection of Crohn's disease and particular genetic markers in patients at risk for celiac disease. In an oral presentation yesterday at Digestive Disease Week (DDW) in Chicago, Prometheus reported a...

2009-06-01 15:01:13

 Researchers are making great strides in understanding the development and treatment of inflammatory bowel disease, a chronic inflammatory condition of the digestive tract that affects more than a half million Americans, according to several studies being presented at Digestive Disease Week® 2009 (DDW®). DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal...

2009-05-19 07:00:00

First-in-class Oral Therapeutic for IBD with Novel Mode of Action MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease will be presented in an oral session at the upcoming 2009 Digestive Disease Week (DDW) meeting. Traficet-EN is an...

2009-05-19 05:00:00

Developed by a Crohn's patient with help from GI specialists, GI Monitor, an iPhone App launched by WellApps, Inc., allows patients with (IBD) Crohn's and Ulcerative Colitis to track their symptoms and deliver accurate data to their doctors. UPPER SADDLE RIVER, N.J., May 19 /PRNewswire/ -- WellApps, Inc. launched an iPhone application to help people with (IBD) Crohn's and Ulcerative Colitis provide accurate symptom data to their doctors for optimal treatment. The application, called GI...